Research programme: lamellarins - PharmaMar

Drug Profile

Research programme: lamellarins - PharmaMar

Alternative Names: Lamellarin D

Latest Information Update: 14 Apr 2009

Price : $50

At a glance

  • Originator PharmaMar
  • Class Alkaloids
  • Mechanism of Action DNA topoisomerase I inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Apr 2009 Discontinued - Preclinical for Cancer in Spain (unspecified route)
  • 05 Dec 2007 This programme is still in active development
  • 05 Aug 2005 This programme is still in active development - (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top